يعرض 1 - 7 نتائج من 7 نتيجة بحث عن '"Judith Bushong"', وقت الاستعلام: 0.80s تنقيح النتائج
  1. 1
    Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227

    المؤلفون: Julie R. Brahmer, Jong-Seok Lee, Tudor-Eliade Ciuleanu, Reyes Bernabe Caro, Makoto Nishio, Laszlo Urban, Clarisse Audigier-Valette, Lorena Lupinacci, Randeep Sangha, Adam Pluzanski, Jacobus Burgers, Mauricio Mahave, Samreen Ahmed, Adam J. Schoenfeld, Luis G. Paz-Ares, Martin Reck, Hossein Borghaei, Kenneth J. O'Byrne, Ravi G. Gupta, Judith Bushong, Li Li, Steven I. Blum, Laura J. Eccles, Suresh S. Ramalingam

    المصدر: Journal of Clinical Oncology. 41:1200-1212

    مصطلحات موضوعية: Cancer Research, Oncology

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d8b4a140d7d0dc05447ae536d36a8ed
    https://doi.org/10.1200/jco.22.01503

    أضف إلى المفضلة
  2. 2
    Systemic and intracranial outcomes with first-line nivolumab plus ipilimumab in patients with metastatic non–small cell lung cancer and baseline brain metastases from CheckMate 227 Part 1

    المؤلفون: Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, Michael Schenker, Bogdan Zurawski, Sang-We Kim, Mauricio Mahave, Aurelia Alexandru, Solange Peters, Adam Pluzanski, Reyes Bernabe Caro, Helena Linardou, Jacobus A. Burgers, Makoto Nishio, Alex Martinez-Marti, Koichi Azuma, Rita Axelrod, Luis G. Paz-Ares, Suresh S. Ramalingam, Hossein Borghaei, Kenneth J. O’Byrne, Li Li, Judith Bushong, Ravi G. Gupta, Diederik J. Grootendorst, Laura J. Eccles, Julie R. Brahmer

    المصدر: Journal of Thoracic Oncology.

    مصطلحات موضوعية: Pulmonary and Respiratory Medicine, Oncology

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::74bfa2da3b17b9b98ecf986a2fa8bc01
    https://doi.org/10.1016/j.jtho.2023.04.021

    أضف إلى المفضلة
  3. 3
    Abstract CT081: Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in Chinese patients (pts) with resectable NSCLC in CheckMate 816

    المؤلفون: Changli Wang, Ke-Neng Chen, Qixun Chen, Lin Wu, Qun Wang, Xiaofei Li, Kejing Ying, Wenxiang Wang, Jian Zhao, Lunxu Liu, Junke Fu, Chunfang Zhang, Jichun Liu, Yi Hu, Mark M. Awad, Ives Ntambwe, Junliang Cai, Judith Bushong, Phuong Tran, Shun Lu

    المصدر: Cancer Research. 83:CT081-CT081

    مصطلحات موضوعية: Cancer Research, Oncology

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::71bb40f5cb1bc8f70b8b8f7e5d71eace
    https://doi.org/10.1158/1538-7445.am2023-ct081

    أضف إلى المفضلة
  4. 4
    First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

    المؤلفون: A. Vergnenegre, A. Alexandru, Hiroshi Sakai, Helena Linardou, Michael Schenker, Claudia Caserta, László Urbán, Judith Raimbourg, Jacobus A. Burgers, Arteid Memaj, Suresh S. Ramalingam, Matthew D. Hellmann, Randeep Sangha, Martin Reck, Julie R. Brahmer, Mariano Provencio, Ki Hyeong Lee, Sang-We Kim, Clarisse Audigier-Valette, Luis Paz-Ares, Yuichiro Ohe, Hossein Borghaei, Kenneth J. O'Byrne, L. Lupinacci, Phuong Tran, Jong Seok Lee, Makoto Nishio, Kynan Feeney, Masayuki Takeda, Enric Carcereny, Adam Pluzanski, F. E. Nathan, Carlos Gallardo, Judith Bushong, Keunchil Park, B. Zurawski, Tudor-Eliade Ciuleanu, Reyes Bernabe Caro, Gregory A. Otterson

    المساهمون: Bristol-Myers Squibb, Ono Pharmaceutical

    المصدر: Journal of Thoracic Oncology
    r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
    instname

    مصطلحات موضوعية: Pulmonary and Respiratory Medicine, Oncology, Adult, medicine.medical_specialty, Lung Neoplasms, Immunotherapy, First line, medicine.medical_treatment, Ipilimumab, PD-1 checkpoint inhibitor, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Clinical endpoint, Humans, Chemotherapy, CTLA-4, First-line, business.industry, Confidence interval, Discontinuation, Nivolumab, Metastatic non–small cell lung cancer, Open label, Neoplasm Recurrence, Local, business, medicine.drug

    وصف الملف: application/pdf

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36f7125153a7a538998a341b2f60e83e
    http://hdl.handle.net/10261/305831

    أضف إلى المفضلة
  5. 5
    Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for metastatic non–small cell lung cancer (NSCLC): Results from CheckMate 227

    المؤلفون: Julie R. Brahmer, Jong-Seok Lee, Tudor-Eliade Ciuleanu, Reyes Bernabe Caro, Makoto Nishio, Lazlo Urban, Clarisse Audigier-Valette, Lorena Lupinacci, Randeep S. Sangha, Luis G. Paz-Ares, Martin Reck, Hossein Borghaei, Kenneth John O'Byrne, Ravi Gupta, Judith Bushong, Li Li, Steven I. Blum, Laura Eccles, Suresh S. Ramalingam

    المصدر: Journal of Clinical Oncology. 40:LBA9025-LBA9025

    مصطلحات موضوعية: Cancer Research, Oncology

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::25b86cc9b16d800390e7cefe725f1c5c
    https://doi.org/10.1200/jco.2022.40.17_suppl.lba9025

    أضف إلى المفضلة
  6. 6
    Neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo for resectable (IB–IIIA) non-small cell lung cancer (NSCLC): Association of pathological regression with event-free survival (EFS) in CheckMate 816

    المؤلفون: Mariano Provencio-Pulla, Jonathan Spicer, Janis M. Taube, Claudio Martin, David R. Spigel, Changli Wang, Nicolas Girard, Shun Lu, Tetsuya Mitsudomi, Mark M. Awad, Enriqueta Felip, Julie R. Brahmer, Stephen Broderick, Scott Swanson, Keith Kerr, Li Li, Junliang Cai, Judith Bushong, Phuong Tran, Patrick M. Forde

    المصدر: Journal of Clinical Oncology. 40:LBA8511-LBA8511

    مصطلحات موضوعية: Cancer Research, Oncology

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::f5a0148465c785b63cc5ea93317282bb
    https://doi.org/10.1200/jco.2022.40.17_suppl.lba8511

    أضف إلى المفضلة
  7. 7
    Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227

    المؤلفون: Hiroshi Sakai, Phuong Tran, Jong Seok Lee, Martin Reck, Yuichiro Ohe, László Urbán, Makoto Nishio, Arteid Memaj, Kenneth J. O'Byrne, Tudor-Eliade Ciuleanu, Suresh S. Ramalingam, Keunchil Park, Julie R. Brahmer, Matthew D. Hellmann, Adam Pluzanski, Reyes Bernabe Caro, Judith Bushong, Luis Paz-Ares, Hossein Borghaei

    المصدر: Journal of Clinical Oncology. 39:9016-9016

    مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, Chemotherapy, business.industry, medicine.medical_treatment, First line, non-small cell lung cancer (NSCLC), Ipilimumab, medicine.disease, Internal medicine, Overall survival, Medicine, In patient, Nivolumab, business, Programmed death, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::c280294aca93e35cb51b506c5c69e2fe
    https://doi.org/10.1200/jco.2021.39.15_suppl.9016

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء